EZH2, a novel therapeutic target in Adrenal Cortex Cancer

EZH2, a novel therapeutic target in Adrenal Cortex Cancer

Adrenal cortex Cancer is one of the most aggressive cancers, for which there is no effective therapeutic approach. Research supervised by Pierre VAL at GReD laboratories, identified overexpression of EZH2 as a novel alteration involved in malignant progression of this cancer. These data show that targeting EZH2 with pharmacological inhibitors blocks proliferation of cancer cells and induces cell death. This suggests that EZH2 could be an interesting target for treatment of adrenal cancer. This article is published in Human Molecular Genetics (Drelon et al., 2016)

This work has been highlighted on the CNRS website (in French)


For more informations ….

Drelon C, Berthon A, Mathieu M, Ragazzon B, Kuick R, Tabbal H, Septier A, Rodriguez S, Batisse-Lignier M, Sahut-Barnola I, Dumontet T, Pointud JC, Lefrançois-Martinez AM, Baron S, Giordano TJ, Bertherat J, Martinez A and Val P

EZH2 is overexpressed in Adrenocortical Carcinoma and is associated with disease progression.

Hum. Mol. Genet. first published online May 5, 2016 doi:10.1093/hmg/ddw136


Pierre Val    Email : Pierre.VAL@univ-bpclermont.fr

Last modified: 02/07/2019